ASIAN JOURNAL OF PHARMACEUTICAL AND BIOLOGICAL RESEARCH





Editorial board

Dr. Madhu Bala Scientist 'F' and Joint Director, Institute of Nuclear Medicine and Allied Sciences (INMAS), India Dr. Sandip Narayan Chakraborty Research Asst, Translational Molecular Pathology, Ut Md Anderson Cancer Center, Life Sciences Plaza, Houston, TX 77030 Dr. Tushar Treembak Shelke Head of Department of Pharmacology and Research Scholar, In Jspms Charak College of Pharmacy & Research, Pune, India Dr. Subas Chandra Dinda Professor-cum-Director: School of Pharmaceutical Education & Research (SPER), Berhampur University, Berhampur, Orissa, India. Dr. Jagdale Swati Changdeo Professor and Head, Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, S.No.124, MIT Campus, Kothrud, Pune-411038 Dr. Biplab Kumar Dev Principal, Department of Pharmacy, Assam downtown University, Sankar Madhab Path, Panikhaiti 781026, Guwahati, Assam, India Dr. Yogesh Pandurang Talekar Research Associate, National Toxicology Centre Dr. Indranil Chanda Assistant Professor, Girijananda Chowdhury Institute of Pharmaceutical Science, Hathkhowapara, Azara Guwahati-17, Assam, India. Dr. Sudip Kumar Mandal Department of Pharmaceutical Chemistry, Dr. B. C. Roy College of Pharmacy & AHS, Bidhannagar, Durgapur-713206, India. Sodikova Dilrabokhon Andijan state medical institute Dr., associate professor Kuryazova Sharofat Tashkent Pediatric medical institute Dr., Abdurakhmanova Nigora Nazimovna Tashkent Pediatric Medical Institute Abdullaeva Umida Bukhara state medical institute Dr. Neeraj Upmanyu Prof., Peoples Institute of Pharmacy & Research Center, Bhopal, MP, India. Dr. Mirrakhimova Maktuba Khabibullaevna Tashkent medical academy Uzbekistan Dr. Nishanova Aziza Abdurashidovna, Tashkent State Dental Institute Dr. Sadikova Minurakhon Adkhamovna Andijan State Medical Institute Kurbanova Sanobar Yuldashevna Tashkent State Dental Institute Zokirova Nargiza Bahodirovna Tashkent Pediatric medical institute Khabilov Behzod Nigmon ugli Tashkent State Dental Institute Dr. Domenico De Berardis Department of Mental Health, Azienda Sanitaria Locale Teramo, 64100 Teramo, Italy Dr. Azizova Rano Baxodirovna associate professor of the Department of neurology of the Tashkent Medical Academy Dr. Ishankhodjaeva Gulchekhra Tashkent Medical Academy Institute of Nuclear Medicine and Allied Sciences (INMAS), India Brig SK Mazumdar Marg, Timarpur, New Delhi, Delhi 110054 India

ASSESSMENT OF MENTAL-EMOTIONAL CHANGES IN IRRITABLE BOWEL SYNDROME USING CLINICAL METHODS

Makhmudova Lola Izzatiloevna Bukhara State Medical Institute, Bukhara, Uzbekistan

Annotation Irritable bowel syndrome affects the emotional and mental state of patients, their social activity, professional activity and family relationships. 82 patients were selected for the study. Of these, 49 were the diarrhea-dominated type of IBS and 33 were the constipation-dominated type. The average age of patients is 33.2 ± 0.8 years. Mild to moderate levels of depression have been found to dominate the irritable bowel syndrome accompanied by a predominance of diarrhea compared to the type of suppressor with a predominance of constipation. No equally severe levels of depression were found in either group. It can be seen from this that an increase in the number of seizures affects the mental and emotional activity of patients, leading to the appearance of depressed states of varying degrees.

Keywords: irritable bowel syndrome, depression, Sung scale

Irritable bowel syndrome (IBS) significantly worsens the quality of life of patients, since the incidence is 19-40 years old.

ITS affects the emotional and mental state of patients, their social activity, professional activities and family relationships [5].

ITS causes economic damage due to the direct costs and indirect indicators of medical examination, including temporary disability.

Thus, direct medical costs, including medical examinations and treatment, are estimated at \$1.6–10.5 billion per year in the United States (US). Indirect costs (temporary disability compensation) - more than 20 billion dollars per year. The total estimated cost of IBS in the United States is estimated at 20-25 billion dollars per year [2,6-13]. These costs are greater than the estimated cost of a chronic disease such as bronchial asthma, which is estimated at \$16 billion per year.

According to estimates, IBS origin has been shown to reduce labor productivity by up to 21% per week, thereby increasing employer costs [1,3].

The Korea National Insurance Company, which covers nearly 100 percent of South Korea's population, analyzed the 2008 IBS patient database using MKB-10 (codes K58, K58.0, K58.9). The prevalence of IBS was 2.3-9.6% of the Korean population, depending on the region. In 2008, total IBS costs approached \$559 million, of which direct medical costs accounted for 59.7%. The direct economic damage caused by IBS is very high and has been equal to 0.46% of the national

The purpose of the study is to determine the level of depression in patients with irritable bowel syndrome.

Research material and methods. The study was conducted in the department of gastroenterology of the multidisciplinary medical center of Bukhara region, and 82 patients treated in the inpatient setting with IBS were selected. The diagnosis of IBS was made based on the Rome IV criteria (2016), and the Bristol scale of stool patterns was used to determine the clinical form of IBS. The average age of patients is 33.2 ± 0.8 years.

Patients with IBS were divided into two groups: non-refractory (IBSn – 35 patients) and refractory (IBSr – 47 patients) of IBS. Depending on the expression of clinical symptoms, patients with IBSn-d (diarrhea) - 21 (25.6%), IBSn-c (constipation) - 14 (17%), IBSr-d - 28 (34.2%) and IBSr-c – divided into 19 people (13.2%).

The Tsung scale was used to determine the level of depression in patients. The Zung Self-Rating Depression Scale is a self-rating depression test developed by psychiatrist Dr. William Tsung at Duke University. The test measures the level of depression of patients and determines the degree of depressive disorders. The Tsung scale can be used by the examinee or physician to self-examine or screen for depression. The Tsung scale test has high accuracy and reliability, which allows to avoid additional economic and time costs related to medical examination in ethical issues.

The test takes into account 20 factors that define four levels of depression. There are ten positive and ten negative questions in the test. Each question is evaluated on a scale from 1 to 4 (based on these answers: "never", "sometimes", "often", "constantly"). The results are divided into four groups:

- 25-49 is normal
- 50-59 mild depression
- 60-69 moderate depression
- 70 or more severe depression.

Research results and discussion. The Tsung questionnaire was used to assess the psycho-emotional state of patients with irritable bowel syndrome. When summarizing survey data on the Tsung scale, 19% of patients with non-refractory IBS had no depression (less than 50 points), 28.7% had mild depression (50-59 points), and 52.3% had moderate depression (60-69 points) (table 1).

The degree of development of depression in patients depending on the types of irritable bowel syndrome

Types of	No depression			Mild depression			Moderate depression		
IBS	n	(%)	grade M±	n	(%)	grade	n	(%)	grade
			m			M± m			M± m
IBSn-d	4	19#	45.5±1.4	8	38.1*	53.5±0.6	9	42.9#	61.7±0.5
n=21									
IBSn-c	3	21.4#*	47.7±0.9	5	35.7	53.0±1.1	6	42.9#	62.1±0.7
n=14									
IBSr-d	4	14.3#	44.5±2.1	13	46.4#	54.2±0.8	11	39.3#	62.5±0.5
n=28					**				
IBSr-c	5	26.3#	47.4±0.7	6	31.6	53.6±0.8	8	42.1#	63.9±0.8
n=19		**						**	
Control	13	65	41.3±1.3	7	35	53.7±0.7	0	0	0
group									
n=20									

Explanation: IBSn-d - non-refractory IBS type with diarrhea; ITSn-c - non-refractory IBS type with constipation; IBSr-d - a type of refractory ITS with diarrhea; ITSr-c - refractory type of IBS with constipation; #-the difference between the indicators of the control group (p < 0.05); *-the difference between the indicators of the group of non-refractory patients (p < 0.05); **- difference between the indicators of the group of refractory patients (p < 0.05).

Depression was not observed in 19.2% of patients with refractory IBS (less than 50 points), mild depression (50-59 points) in 40.4% cases, moderate depression (60-69 points) in 40.4% cases.

In order to provide a more accurate assessment of the mental-emotional state of patients, the indicators in each subgroup were analyzed according to gender (table 2).

Table 2

Gender dependence of the development of depression in patients with irritable bowel syndrome

Types of IBS	Sex	No depression Mile		Mild dep	Aild depression		Moderate depression	
		An. no	(%)	An. no	(%)	An. no	(%)	
ITSn-d	Male	2	9.5	4	19.1	5	23.8*	
n=21	Female	2	9.5	4	19.1*	4	19.0	
ITSn-q	Male	2	14.3*	4	28.6*	0	0	
n=14	Female	1	7.1	1	7.1	6	42.3*	
ITSr-d	Male	2	7.1	6	21.4**	7	25.0	
n=28	Female	2	7.1	7	25.0**	4	14.4	

ITSr-q	Male	1	5.3	2	10.5	6	31.6**
n=19	Female	4	21.1**	4	21.1	2	10.5

Note: IBSn-d is a type of non-refractory IBS with diarrhea; ITSn-c - non-refractory IBS with constipation; IBSr-d - a type of refractory IBS with diarrhea; ITSr-c - refractory type of IBS with constipation; *- the difference between the indicators of the group of non-refractory patients (p < 0.05); **- difference between the indicators of the group of refractory patients (p < 0.05).

When psycho-emotional characteristics were studied by gender, it was observed that men with IBSn-c had a predominance of depression developed at a mild level (28.6%) compared to other subgroups, while in women, a moderate level of depression (42.3%) prevailed.

Quality of life indicators were analyzed using the MOS SF-36 questionnaire.

The physical component of health covers the following indicators:

- Participation Activity (RP)
- Physical activity (PF)
- Pain (P)
- General health (GH)

The mental component of health includes the following indicators:

- Vitality (VT)
- Social Activity (SF)
- Emotional Activity (RE)
- Mental Health (MH)

The results of the analysis of indicators of mental and physical components of health in groups of patients with ITS and healthy people are presented in table 3.

Table 3

Mental and physical components of quality of life in patients with irritable bowel
syndrome, (M±m)

	Control group, n=20	ITS n=35	ITSr, n=47	р
The mental component of health (MH)	51.6±0.4	37.9±0.2**	38.7±0.8**	< 0.005
Physical component of health (PH)	54.1±0.3	44.3±0.7**	36.4±0.5**	< 0.005
The pl	ysical compo	nent of health		
Pain	92.9±0.3	64.3±0.3**	59.0±0.6**	< 0.005
General health	76.6±0.4	53.2±0.3**	50.0±0.4**	< 0.005
Participatory activities	66.4±0.6	53.7±0.2**	50.1±0.2**	< 0.005

MITT 1100: 2025								
Physical activity	81.4±0.5	83.2±0.3**	79.8±0.7	>0.05				
The physical component of health								
Vitality	68.8±0.4	44.5±0.3**	40.7±0.9**	< 0.005				
Mental health	69.2±0.3	48.2±0.2**	40.4±0.3**	< 0.005				
Social activity	84.2±0.3	61.3±0.2**	58.3±0.5**	< 0.005				
Emotional activity	81.7±0.5	53.3±0.2**	49.3±0.4**	< 0.005				

Note: **-Difference between IBS and healthy individuals (p< 0.005)

As shown in table 3, mental and physical components of health of patients with ITS are statistically significantly reduced compared to healthy people, emotional and physical condition of patients limits their daily work and physical activity.

In the group of patients with IBSr, the pain index decreased statistically significantly (p<0.005), which affects the implementation of daily activities, including work at home and outside the home. In the group of patients with IBSr, the general health indicators are significantly lower (p<0.005), which reflects the low assessment of the patient's health status, as well as treatment prospects. In the group of refractory IBS, participation activity is significantly lower than in healthy people. Only the physical activity index did not show significant changes in both groups of patients and controls (p=>0.05).

From the data in Table 3, the analysis of the scales that make up the mental component of health shows that in patients with IBSr, compared to healthy people, the indicator of emotional functioning is significantly reduced (p<0.005), it is limitation in communication, difficulty in performing work or other activities, disturbed mental state causes a decrease in the volume or quality of the work performed.

The social activity index was found to be statically significantly lower in patients with refractory IBS compared to healthy patients, indicating that the physical or mental condition of IBS patients limits social activity (communication).

The vital activity (vitality) and mental health indicators in patients with IBSr are significantly lower than in the healthy group (p<0.005), which indicates that patients with IBS underestimate the vital activity, they often feel tired and exhausted, anxiety, compared to healthy people. and are more likely to have symptoms of depression, feelings of mental exhaustion, and an overwhelming sense of negative emotions.

An analysis of the mental and physical components of health among the types

Asian journal of Pharmaceutical and biological research 2231-2218 http://www.ajpbr.org/ Universal IMPACT factor 7 SJIF 2022: 4.465 Volume 12 Issue 2 MAY-AUG. 2023 of irritable bowel syndrome is presented in table 4.

Table 4

Analysis of mental and physical components of health among types of irritable bowel syndrome, (M±m)

	IBSn-d, n=21	IBSn-c, n=14	IBSr-d, n=28	IBSr-c, n=19	R
The mental component of health (M h)	37.9±0.3**	38.0±0.3**	34.9±0.4	44.3±0.5	** <0.005
Physical component of health (PH)	46.6±0.6**	40.8±0.7*	35.5±0.6	37.8±0.8	* <0.05

Note: IBSn-d is a type of non-refractory IBS with diarrhea; IBSn-c - non-refractory IBS with constipation; IBSr-d - a type of refractory IBS with diarrhea; IBSr-c - refractory type of IBS with constipation; ** - p<0.005

A comparative analysis of the components of health in different clinical types of IBS (table 4) showed that mental $(34.9\pm0.4, p<0.005)$ and physical $(35.5\pm0.6, p<0.05)$ of health in IBSr-d component was found to be significantly lower compared to other subgroups.

Summary. Thus, it was found that the mild and moderate level of depression prevailed in the diarrhea-predominant bowel syndrome compared to the constipation-predominant type. Neither group was found to have the same level of severe depression. It can be seen that the increase in the number of bowel movements affects the psycho-emotional activity of patients and leads to the appearance of various levels of depression.

List of references

1. Burbige EJ Irritable bowel syndrome: diagnostic approaches in clinical practice / EJ Burbige // Clinical and Experimental Gastroenterology. 2010. - Vol. 3. - P. 127-137.

2. Chey WD Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation / WD Chey et. al. // Aliment Pharmacol Ther. 2012. - Vol. 35(5). - P. 587-599.

3. Dean BB Impairment in work productivity and health-related quality of life in patients with IBS / BB Dean et al. // Am J Manag Care. 2015. - Vol. 11(1 Suppl). -P. S17-S26.

4. Jung HK Estimating the burden of irritable bowel syndrome: analysis of a nationwide Korean database / HK Jung et al. // J Neurogastroenterol Motil. 2014. - Vol. 20(2). - P. 242-52.

5. Mikhailova T.L. Kachestvo jizni bolnyx s syndromem razdrajennogo kishechnika / T.L. Mikhailova and dr. // Rossiyskiy Journal of Gastroenterology, Hepatology and Coloproctology. 2017. - No. 6 - S. 70-75.

6. Abdullayev R. B., Makhmudova L.I. Features of Chemical Elements in Various Forms of Irritable Bowel Syndrome // Annals of R.S.C.B., ISSN:1583-6258, Vol. 25, Issue 2, 2021, Pages. 2993 – 3000.

7. Abdullayev R.B., Makhmudova L.I. Micro elemental imbalance in irritable bowel syndrome and IBS correction. Academicia. Vol. 11, Issue 5, May 2021:655-662.

8. Abdullayev R.B., Makhmudova L.I., (2021). Assessment Of Clinical And Psychological Status And Quality Of Life Of Patients In Different Forms Of Irritable Bowel Syndrome. The American Journal of Medical Sciences and Pharmaceutical Research, 3(02), 127-134.

9. Makhmudova L.I, Akhmedova N.Sh. Irritable bowel syndrome: a new look at the problem // Academicia. 10.5958/2249-7137.2020.00983.0. 433-38.

10. Makhmudova L.I., Akhmedova N.Sh., Ergashov B.B. Clinical manifestation of irritable bowel syndrome. Art of medicine. International medical scientific journal. Vol. 1, Issue 2. 2021:24-33.

11. Makhmudova L.I., Ismatova M.N., Mukhamedjanova M.H., Sulaymonova G.A. Evaluation of microelement status and IBS correction with irritable bowel syndrome. New day in medicine. 2(34) 2021:325-331.

12. Makhmudova L.I., Shazhanova N.S., Akhmedova N.Sh., (2021). Clinical Features Of Irritable Intestinal Syndrome. The American Journal of Medical Sciences and Pharmaceutical Research, 3(04), 154-159.

103

Asian journal of Pharmaceutical and biological research <u>2231-2218</u> <u>http://www.ajpbr.org/</u> <u>Universal IMPACT factor 7</u> <u>SJIF 2022: 4.465</u> Volume 12 Issue 2 MAY-AUG. 2023 13. Makhmudova L.I., Sharipov J.N. State

13. Makhmudova L.I., Sharipov J.N. State of intestinal microflora in irritable bowel syndrome. Tematics journal microbiology. Vol.6, Issue 1. 2022:104-109.